Managing Partner
Upstream Partners
Burt Zweignhaft, PhD, DLitt, Managing Partner, Upstream Partners, is a key industry thought leader and accomplished executive within the specialty-biotech pharmaceutical and oncology cancer care ecosystems. Over the last 20 years Burt has incubated and launched specialty bio-pharmaceuticals with industry leaders like Genzyme, Pharmacyclics, Gilead, Janssen, Pfizer, Alexion, Bayer, GSK, Seattle Genetics, Sanofi, Monogram Science, Roche, Genentech, CureVax, Genomic Health, Janssen and numerous emerging biotech incubators.
Previously CEO, Vice Chairman & Founder of Onco360, a national oncology pharmacy care management provider for a full continuum of oncology pharmacy service to over 3,000 community and hospital based Hematologists, Oncologists and Cancer Centers of Excellence under managed care contracts for 45 million lives. Under Mr. Zweigenhaft's vision and leadership, Onco360 developed the industry standards for an oncology pharmacy best practice model by incorporating the strengths of Board Certified Oncology Pharmacists and Oncology Patient Advocates to support the prospective and concurrent patient centered oncology medical home model.
Burt previously served as Senior Vice President of Managed Care Sales and Marketing, Government Programs, Trade Relations and Business Development Strategies for Priority Healthcare Corporation, a publicly traded company in the specialty pharmacy sector with $2.3 billion in specialty drug revenues before being acquired by Express Scripts in 2005. Prior to 2002, Burt spent several years serving as a specialty pharmacy consultant to Medco, CuraScript, BioScrip and several Regional National Blue Cross Blue Shield and National Managed Care Payer programs.
Burt serves as Editor and Chief of the Journal for Value Based Cancer Care. Burt is also Co-Chairman and Co-Founder of the AVBCC (Association for Value Based Cancer Care). Philanthropically, Burt serves on the National Board of Swim Across America for Cancer. In 2015 Mr. Zweigenhaft was honored to be the recipient of the CancerCare “Help and Hope Award”.
Disclosure information not submitted.
Saturday, March 12, 2022
1:45pm – 2:45pm CT
